Glenmark Pharmaceuticals Limited has informed the Exchange about U.S. FDA inspection at the Company's Facility at Monroe, North Carolina, USA
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The U.S. Food & Drug Administration (USFDA) carried out a Good Manufacturing Practice (GMP) inspection at Glenmark's manufacturing facility in Monroe, North Carolina, USA from June 9 to June 17, 2025. At the end of the inspection, the company was issued a Form 483 with five observations. The company clarified that all five observations are procedural in nature and there were no observations related to data integrity. Glenmark stated it will work closely with the USFDA to address the observations and respond within the stipulated timeline.
Form 483 is a routine regulatory communication and procedural observations are generally considered less serious. The absence of any data integrity observations is a positive signal, and the market is unlikely to view this as a material adverse event unless the observations escalate into a Warning Letter or import alert in the future.